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Antigen-speciﬁc interventions are desirable approaches in Type 1 Diabetes (T1D) as they can alter islet-
speciﬁc autoimmunity without systemic side effects. Glutamic acid decarboxylase of 65 kDa (GAD65) is a
major autoantigen in type 1 diabetes (T1D) and GAD-speciﬁc autoimmunity is a common feature of T1D
in humans but also in mouse models of the disease. In humans, administration of the GAD65 protein in
an alum formulation has been shown to reduce C-peptide decline in recently diagnosed patients,
however, these observations were not conﬁrmed in subsequent phase II/III clinical trials. As GAD-based
immune interventions in different formulations have successfully been employed to prevent the
establishment of T1D in mouse models of T1D, we sought to analyze the efﬁcacy of GAD-alum treatment
and the effects on the GAD-speciﬁc immune response in two different mouse models of T1D. Consistent
with the latest clinical trials, mice treated with GAD-alum were not protected from diabetes, although
GAD-alum induced a GAD-speciﬁc Th2-deviated immune response in transgenic rat insulin promoter-
glycoprotein (RIP-GP) mice. These observations underline the importance of a thorough, preclinical
evaluation of potential drugs before the initiation of clinical trials.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Type 1 diabetes (T1D) is an autoimmune disease leading to
destruction of the insulin producing pancreatic beta (b)-cells, per-
manent dysregulation of blood glucose homeostasis, a lifetime of
dependence on insulin injections or infusions, and often inevitable
and severe microvascular complications [1,2]. It is without question
that a cure is needed for T1D, but past and current efforts in this
direction have been met by many challenges. In attempts to pre-
serve b-cell function in patients with recent-onset diabetes, inter-
vention trials have included antigen-speciﬁc therapies and systemic
immunosuppressants as well as anti-inﬂammatory drugs [3e10].ase of 65 kDa; T1D, type 1
cytic choriomeningitis virus;
mor necrosis factor; IFN-g,
cells; IL, interleukin; Th, T-
tyric acid.
: þ1 858 752 6993.
).
r Ltd. Open access under CC BY licensMany of these trials suffered from lack of efﬁcacy, and those that
initially showed some promise resulted in only transient preserva-
tion of b-cell or serious adverse effects due to immunosuppression
[11]. However, b-cell antigen-speciﬁc therapies remain particularly
appealing as they have the potential to restore immunological
tolerance to b-cell antigens without systemic immunosuppression.
Glutamic acid decarboxylase of 65 kDa (GAD65) is one of the
major autoantigens in human T1D. GAD is found in the central
nervous system where it catalyzes the conversion of the neuro-
transmitter glutamate to GABA. It is also found in pancreatic b-cells
where its functional role remains largely unknown [12e14]. The
emergence of GAD-speciﬁc autoantibodies occurs prior to b-cell
cell destruction in most cases [15,16], and while GAD autoanti-
bodies have not been causally linked to the T-cell mediated auto-
immune attack, they serve as a clear predictor and marker of the
disease process [17,18]. Previous preclinical studies have shown
that GAD vaccines have the potential to halt the progression of
diabetes in the NOD mouse models of T1D [19,20]. However, Phase
II/III clinical trials in recent-onset T1D patients treated with GAD-
protein in an alum formulation have shown discordant results. A
70-patient human trial conducted in Sweden, showed that treat-
ment with two doses of 20 mg alum-formulated GAD induces
tolerance to GAD resulting in preservation of b-cell insuline.
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months) T1D [21]. Unfortunately, these effects could not be
reproduced by subsequent clinical trials with the same drug
[22,23]. The reasons for these discrepancies are not entirely un-
derstood but may lie in the relatively low number of patients in the
initial promising sub-group, or inﬂuenza vaccination campaigns
concurrent with the enrollment of the patients in the Phase III trial
that may have impaired patients’ immune responses [22].
As GAD-based interventions have previously shown efﬁcacy in
mouse models of T1D but alum-formulated GAD has never been
tested in murine disease, we revisited the preclinical realm by
testing its efﬁcacy with several doses, frequencies and mouse
models of the disease. In the present study, we aimed to elucidate
whether prevention of diabetes could be achieved using GAD-alum
at several doses and frequencies in two mouse models, the non-
obese diabetic (NOD) mouse, which spontaneously develops T1D,
and the transgenic RIP-LCMV-GP mouse, in which b-cells express
the glycoprotein (GP) from lymphocytic choriomeningitis virus
(LCMV) on their surface and the disease is induced upon LCMV
infection.We also examined the cytokine and autoantibody proﬁles
using ELISA and phenotype of T-cell subsets through ﬂow cytom-
etry in order to shed light on GAD’s mechanism of action.
2. Materials and methods
2.1. Mice
NOD/ShiLt mice were purchased from Jackson Laboratories and
housed in speciﬁc-pathogen free conditions at La Jolla Institute for
Allergy and Immunology (LIAI). Transgenic rat insulin promoter
(RIP)-lymphocytic choriomeningitis virus (LCMV)- glycoprotein
(GP) mice, as previously described [24], were bred in-house under
the same conditions and transferred to an infectious suite prior to
treatments and infection. A single dose of 1  104 plaque-forming
units (PFU) of LCMV Armstrong was injected intraperitoneally in
order to induce diabetes (usually by day 8e12 post-infection). In
both mouse models, blood glucose values (BGVs) were recorded 1e
2 times a week with an AccuCheck Glucometer (LifeScan Inc.,
Milpitas, CA, USA) and mice were considered diabetic with BGVs
above 250mg/dl. For mechanistic studies, mice were euthanized by
CO2 asphyxiation and cervical dislocation per animal protocol.
2.2. Treatments
Stock solutions of 40 mg/ml GAD-Alum and placebo containing
only alum were provided by Diamyd Medical AB (Sweden) and
injected subcutaneously in anesthetized mice.
2.3. Enzyme-linked immunosorbent assays (ELISAs)
2.3.1. Cytokines
Detection of interleukin (IL)-5 and tumor necrosis factor (TNF)
in culture supernatants were performed with ELISA kits purchased
from eBioscience (San Diego, CA) according to the manufacturer’s
instructions. Other cytokines were detected with Bio-Plex Pro
Mouse Cytokine 23-plex Assay (Bio-Rad, cat. # M60-009RDPD)
according to the manufacturer’s instructions.
2.3.2. Autoantibodies
GAD-speciﬁc autoantibodies were measured in Maxisorp Nunc
96-well plates by coating with 2 mg GAD-Alum or Alum alone as a
negative control overnight at þ4C. After 3 washes in PBS 0.05%
Tween and a 1-h blocking step with PBS 10% fetal bovine serum
(FBS) at room temperature (RT), serially diluted serum samples
were added and incubated at RT with agitation for 2 h. As captureantibodies, goat anti-mouse IgG antibodies coupled with horse-
radish peroxidase (LifeTech, cat. # M30107) were diluted 1/1000 in
blocking buffer and incubated with agitation for 1.5 h. Enzymatic
reactions were revealed with the addition of 100 mL/well of TMB
substrate (cat # 421101, Biolegend, San Diego, CA) for 5e10 min.
Reactions were stopped with 100 mL/well of 1 N HCl. Plates were
read with a spectrophotometer measuring absorbance at 450 nm.
2.4. Flow cytometry staining for intracellular Foxp3 and cytokines
At 4 weeks post-infection, spleen and pancreatic lymph nodes
(pLN) were collected from euthanized mice and processed for
further staining. Splenocytes were incubated with 2 mL ACK lysis
buffer for 2 min to lyse red blood cells. Thereafter, pLN cells and
splenocytes were resuspended at 10  106 cells/mL in complete
RPMI (Gibco) containing 10% FBS, 50 mM b-mercaptoethanol, Pen/
Strep, Glutamine and Hepes (all from Gibco). Cells were cultured in
the presence of Brefeldin A (cat. # B7651, Sigma, St. Louis, USA) and
5 mg/mL GP33e41 peptide from LCMV (Abgent Inc, San Diego, USA)
and incubated at 37 C for 4 h. Cells were then stained in FACS
buffer (PBS 0.05% bovine serum albumin) for surface antibodies
(CD8, CD4, CD25) and ﬁxed for 30 min at 4 C using the ﬁxation
reagent from Foxp3 detection kit (cat. # 88-8115-40, eBioscience,
San Diego, USA). Finally, cells were permeabilized using the same
kit and stained for IFN-g, IL-17, TNF (BD Biosciences) as well as
Foxp3, CD107a (eBioscience) and granzyme B (Life Technologies).
All the antibodies were diluted 1/100. Samples were recorded on an
LSRII cytometer (Beckton Dickinson) and analyzed with FlowJo
software (Tree Star).
2.5. In vitro culture with GAD65 peptide libraries
Total splenocytes were collected, teased out and resuspended at
10  106 cells/mL in complete RPMI. Cells were then stimulated
with 11 overlapping pools of peptides from a human GAD65 pep-
tide library. Amino acid sequences and peptide pools have been
previously published [25]. Upon 72-h incubation, supernatants
were collected and frozen until use for the detection of cytokines by
standard ELISA or Bio-Plex assay. In other experiments, cultured
cells were stained with Treg-speciﬁc markers (CD4, CD25, CD127,
Foxp3) as described above.
2.6. Statistics
Data are expressed as mean  standard error of the mean.
Differences in the incidence of diabetes were assessed using the
Log-rank test. Graphs were plotted and statistics calculated with
GraphPad Prism (versions 4 and 5). Comparisons of GAD-Alum
versus placebo groups were performed with two-tailed unpaired
t-tests. p-values <0.05 were considered statistically signiﬁcant.
2.7. Ethics
All the studies were performed in the La Jolla Institute for Al-
lergy and Immunology upon approval of LIAI’s Animal Care and Use
Committee.
3. Results
3.1. Preventive treatment with different doses of GAD-alum did not
protect NOD mice from T1D
A dose response study was performed in non-obese diabetic
(NOD) mice known for spontaneously developing T1D [26]. NOD
mice were assigned to receive two subcutaneous injections of
T. Boettler et al. / Journal of Autoimmunity 44 (2013) 40e4842either 1 mg, 5 mg or 20 mg of GAD-alum or placebo at 8 and 10 weeks
of age. Mice were subsequently monitored for diabetes onset. We
observed that 1 mg GAD-alum (cumulative dose 2 mg) treated mice
presented similar T1D incidence compared to alum treated controls
(87% versus 71%, p ¼ 0.806) (Fig. 1, left panel). Mice that received 5
times more GAD-alum also had comparable incidence in relation to
their respective placebo controls (80% versus 93%, p¼ 0.363) (Fig. 1,
middle panel). Finally, there was a slight tendency toward protec-
tion from T1D when administering mice 20 mg GAD-alum (73%
versus 93% for controls). However, this trend failed to reach sta-
tistical signiﬁcance (p ¼ 0.35) (Fig. 1, right panel). Collectively,
increasing doses of GAD-alum did not protect NOD mice from T1D.
3.2. Preventive treatment with different doses of GAD-alum did not
protect transgenic RIP-GP B6 mice from diabetes development
Previous studies have demonstrated that genetic variations
could dictate the success or failure of therapies that include GAD65-
speciﬁc tolerance induction [25]. Indeed, the combination of non-
mitogenic anti-CD3 and GAD65 DNA plasmid injections was able
to synergistically reverse the course of T1D in recent-onset diabetic
RIP-GP mice on the C57Bl/6 (B6) background, but not in NOD mice.
Therefore, we investigated the efﬁcacy of various doses of GAD-
alum treatments using the transgenic RIP-GP B6 model for dia-
betes [27]. To this aim, RIP-GP mice were infected with LCMV
Armstrong on day 0 andwere administered 2 mg or 10 mg GAD-alum
or placebo on days 2, 8 and 14 post-infection (arrows, Fig. 2A). Upon
8 weeks of observation, mouse groups that received either dose of
GAD-alum presented a moderate but non-signiﬁcant reduction in
glycemia levels compared to their placebo counterparts (Fig. 2A).
On a per-individual basis, there was no signiﬁcant difference in the
proportions of protected versus non-protected mice, as illustrated
in Fig. 2C by cumulated BGVs at day 28 post-infection, i.e., prior to
mechanistic studies performed below.
A major hurdle that needs to be overcome for proper translation
of preclinical data from bench to bedside is the issue of dosing. In
this context, our laboratory and others have previously shown in
mice that successful antigen-speciﬁc therapies with oral insulin did
not follow a linear, but rather a bell-shaped, trend when increasing
doses [28,29], indicating the need for antigen dose titration
whenever possible. This prompted us to perform experiments in
RIP-GP mice where GAD-alum doses and/or frequencies of
administration were signiﬁcantly decreased (three doses of 0.5 mg)
or increased (9 doses of 20 mg). Fig. 2B depicts BGVs in groups of 5e
6 mice per regimen and although mice that received decreased and
increased doses of GAD-alum displayed a trend toward lower BGVs
compared to placebo, these trends were not statistically signiﬁcant1 5g
0 1
0
20
40
60
80
100
8 10 12 14 16 18 20 22 24
weeks of age
%
 
d
i
a
b
e
t
e
s
0 1
0
20
40
60
80
100
8 10 12 1
weeks
%
 
d
i
a
b
e
t
e
s
Place
GAD-
μ μ
Fig. 1. Diabetes incidence in NOD mice treated with GAD-alum. Diabetes incidence (two co
treated with increasing doses (left panel, 1 mg; middle panel, 5 mg; right panel, 20 mg) of
treatment group in each experiment.after 4 weeks of observation. Moreover, the proportion of protected
individuals (one in each group) was comparable in all treatment
groups (not shown).
3.3. RIP-GP mice treated with GAD-alum presented high titers of
GAD autoantibodies
Next, in order to conﬁrm that GAD-alum immunizations
induced the production of anti-GAD65 autoantibodies as was
shown in human patients [21,23], we performed serum titrations at
4 weeks post-infection in RIP-GP mice that were treated three
times with 2 mg GAD-alum or alum alone. Our ﬁndings show that
GAD-alum treated individuals harbored signiﬁcantly increased ti-
ters of GAD65-speciﬁc IgG autoantibodies compared to mice
treated with placebo (Fig. 2D), suggesting that our administration
regimen effectively led to GAD-speciﬁc humoral responses.
3.4. pLN from RIP-GP mice treated with GAD-alum have decreased
proportions of LCMV-speciﬁc CD8 T-cells that produce TNF and
interferon-g
In the RIP-GP model, LCMV-GP33e41-speciﬁc “autoreactive” CD8
T-cells are responsible for the immune-mediated demise of
pancreatic b-cells resulting in diabetes onset [30]. Thus, we
analyzed the GP-speciﬁc CD8 T-cell responses of treated mice 4
weeks post-infection. Spleen and pancreatic lymph node (pLN)
cells were stimulated in vitrowith GP33e41 peptide in the presence
of Brefeldin A and stained for TNF and IFN-g. Our data indicate that
mean LCMV-speciﬁc CD8 T-cell TNF (Fig. 3A, left panel) production
was signiﬁcantly reduced in the pLN of mice administered
GAD-alum compared to their counterparts (1.17  0.2% versus
4.98  1.73%, respectively; p ¼ 0.040). Similarly, IFN-gþTNFþ
double-producing CD8 T-cells were found in lower frequencies
upon GAD-alum treatment (Fig. 3A, right panel). Interestingly, this
decrease appeared to be speciﬁc to pLN since both TNF and/or IFN-g
levels were found to be similar in the spleen (Fig. 3B and not
shown). Nonetheless, after examining the overall cytokine pro-
duction of CD8 T-cells in pLN, we found no difference between
Placebo and GAD-alum treated groups regarding single-producers
of IFN-g, IL-17, CD107a (LAMP-1, surrogate marker for cytotoxic T
lymphocyte degranulation) and Granzyme B (Fig. 3C).
3.5. pLN from RIP-GP mice treated with GAD-alum have increased
proportions of Foxp3-expressing CD4þCD25high T regulatory cells
Furthermore, we examined in parallel the proportions of Foxp3-
expressing T regulatory cells (Tregs) as it has been published thatg02g
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Fig. 2. Blood glucose levels and GAD-speciﬁc immune responses in RIP-GP mice treated with GAD-alum. (A, B) Blood glucose levels in RIP-GP mice treated with GAD-alum or
placebo. Arrows indicate days of treatment, (A) 2 mg or 10 mg of GAD-alum and (B) 0.5 mg or 20 mg GAD-alum. Three placebo mice received the volume corresponding to 20 mg GAD-
alum formulation and 3 mice received the volume corresponding to 0.5 mg GAD-alum formulation on indicated days. (C) Blood glucose values from placebo and GAD-alum
(3  2 mg)-treated mice at time point of mechanistic studies, 28 days post-infection. Dashed line represents the threshold of 250 mg/dl used for diagnosis. (D) GAD autoanti-
bodies in placebo and GAD-alum (3  2 mg)-treated mice. Shown is the last positive dilution above background. **p < 0.01.
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CD4þCD25high Foxp3þ cell frequencies and GAD65-speciﬁc Foxp3
mRNA expression [31,32]. Accordingly, proportions of Tregs were
signiﬁcantly elevated in the pLN of mice treated with GAD-alum
compared to their placebo controls (13.62  1.1% versusedonhpmylcitaercnaPA
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more systemically in the spleen, although approaching statistical
signiﬁcance (p ¼ 0.071) (Fig. 4B). However, we cannot rule out that
Treg function was not optimal. In this regard, we examinedneelpS
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T. Boettler et al. / Journal of Autoimmunity 44 (2013) 40e4844immunomodulatory molecule CTLA-4 and PD-1 expression levels
in Tregs presented in Fig. 4A but failed to observe signiﬁcant dif-
ferences between both groups on a per-cell basis (data not shown).
It is conceivable that this signiﬁcant elevation in cell frequencies,
without any increased suppressive function on a per-cell basis, was
not sufﬁcient to tame the ongoing “self-reactive” immune response.
3.6. Correlative analyses of effector and regulatory T-cell responses
in relation to mouse glycemia
Mechanistic data presented in Figs. 2e4 were analyzed on a per-
mouse basis to assess linear correlations between pLN-derived CD85
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reach statistical signiﬁcance with 10e11 mice per group
(p ¼ 0.098). In contrast, in placebo treated mice, there was a trend
toward positive correlation (Pearson r ¼ þ0.475) that was not
signiﬁcant either (p ¼ 0.16). No association was found when
correlating mouse glycemia to pLN-derived TNF-producing CD8 T-
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analyzed in the pLN of GAD-alum and placebo treated mice pre-
sented a moderate linear relationship.3.7. C57Bl/6 mice treated with GAD-alum presented GAD65-speciﬁc
Th2-deviated immune responses
Administration of GAD-alum in recent-onset diabetic patients
has been shown to induce the production of cytokines including
TNF, IL-10 as well as IL-5 and IL-13 [21,32]. The latter cytokines are
associated with Th2-biased responses, which in animal models of
diabetes have been shown to be protective [33e36]. Here, we iso-
lated splenocytes from GAD-alum treated mice, stimulated cells
in vitrowith a human (h)GAD65 peptide library covering the entire
hGAD65 sequence [25] and assessed cytokine production by ELISA
upon 3-day culture. We found that IL-5 and TNF production was
elevated in response to peptide pools spanning the C-terminal re-
gion of GAD65 (pools 7e10) (Fig. 6A). Interestingly, stimulation
with pool 10 from the hGAD65 library led to the highest IL-5, but no
TNF, production. Additionally, we used the same supernatants to
perform a Bio-Plex assay on samples stimulated with GAD65 pep-
tide pools 1e3 (C-terminal) and pools 9e11 (N-terminal). We ﬁrst
conﬁrmed the increased IL-5 production in samples speciﬁcally
stimulated with pool 10 (data not shown). However, the production
of immunomodulatory cytokine IL-10 was similarly elevated in all
samples whereas IL-4 productionwas somewhat higher in pools 10
and 11 without this being signiﬁcant (Fig. 6B, upper panels). No0
50
100
150
200
p
o
o
l1
p
o
o
l2
p
o
o
l3
p
o
o
l4
p
o
o
l5
p
o
o
l6
p
o
o
l7
p
o
o
l8
p
o
o
l9
p
o
o
l1
0
p
o
o
l1
1
I
L
-
5
 
(
p
g
/m
L
)
A
B
p
o
o
l1
p
o
o
l2
p
o
o
l3
0
50
100
150
200
IL
-
4
 
(
p
g
/m
l
)
p
o
o
l1
p
o
o
l2
p
o
o
l3
p
o
o
l9
p
o
o
l1
0
p
o
o
l1
1
0
500
1000
1500
2000
IL
-
1
0
 (
p
g
/m
l)
p
o
o
l1
p
o
o
l2
p
o
o
l3
0
50
100
150
200
IL
-
1
7
 
(
p
g
/m
l)
Fig. 6. Analyses of GAD-speciﬁc immune responses elicited by GAD-alum. C57BL/6 mice wer
cultures were stimulated with overlapping peptide pools spanning the entire GAD-protein
cytokines by ELISA (A) or Bio-plex assay (B). Data shown are corrected for background (Unsigniﬁcant difference was found across all samples in terms of
proinﬂammatory cytokine IFN-g, IL-17 and IL-6 production (Fig. 6B,
lower panels). Overall, these data conﬁrm that the TCR repertoire of
GAD65-speciﬁc CD4 T-cells is shifted toward the C-terminal
domain of the protein Ref. [25] and further argue for the existence
of non-overlapping GAD65-speciﬁc CD4 Th2-biased responses.3.8. GAD65-speciﬁc Foxp3-expressing CD4 þ CD25high Treg
responses in RIP-GP mice treated with GAD-alum
Despite an increase in the proportions of Foxp3-expressing
Tregs in the pLN of GAD-alum treated animals (Fig. 4), mice were
not protected and we cannot exclude that the underlying reason is
the absence or a lack of speciﬁcity toward GAD65 and other islet-
speciﬁc antigens within the Treg compartment. In order to exper-
imentally address the question of antigen speciﬁcity in Tregs, we
stimulated in vitro splenocytes from placebo or GAD-alum treated
RIP-GP mice with an hGAD65 peptide library and measured Treg
frequencies upon 3-day culture. When analyzing the percentage of
activated CD4þCD25high T-cells, we observed a signiﬁcant increase
in GAD-alum treated mice speciﬁcally upon in vitro re-stimulation
with GAD65 peptide pools spanning the C-terminal region of
GAD65 sequence (pools 9e11). We saw a similar increase when
cells were stimulated with all 11 GAD65 peptide pools together
(Fig. 7). However, when analyzing the percentage of CD127loFoxp3þ
cells within CD4þCD25high cells, we failed to observe any increase
in GAD-alum treated mice (data not shown).p
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Fig. 7. Analyses of GAD-speciﬁc immune responses elicited by GAD-alum. Four weeks
post-LCMV infection and treatments with GAD-alum (2 mg) or placebo, RIP-GP mice
were euthanized, their spleen cells cultured for three days in the presence of 11 pools
of GAD65 peptides spanning the whole sequence of the protein. Upon 3-day culture,
the proportion of Treg cells was assessed by ﬂow cytometry. Data are from one
experiment with 5 mice per group. *P < 0.05 (unpaired, two-tailed Mann Whitney
test).
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In the present study, we demonstrate that GAD-alum treatment
administered prior to diabetes onset in NOD or RIP-LCMV-GP mice
was unable to protect from clinical disease (Figs. 1, 2A and C). On a
per-individual basis, there was no signiﬁcant difference in the
proportions of protected versus non-protected mice (Fig. 2B). This
lack of efﬁcacy to prevent T1D in mice is in line with the failure to
preserve C-peptide levels that was observed in the latest Phase II/III
clinical trials administering diabetic patients with 2e4 doses of
20 mg GAD-Alum [22,23]. One potential issue that has been put
forward to explain the failure of the latest intervention trial
involving GAD-alum treatment [22] is that, compared to the pla-
cebo arm of the study, the two arms with GAD-alum treatments
enrolled more patients under 15 years old in whom disease is
thought to be more aggressive and C-peptide levels decline faster
[22]. And while the RIP-GP mouse model is a rather aggressive
model as well, the failure of GAD-alum to prevent disease in pre-
diabetic NOD mice despite the administration of various doses
does not necessarily support this hypothesis.
Previous publications from our laboratory and others suggest
that the therapeutic window for b-cell antigen delivery (e.g., insulin
given orally) is rather narrow [28,29]. Thus, we assessed whether
higher or lower doses might be more efﬁcacious. In the RIP-GP
model, we gave a maximum dose of 20 mg GAD-Alum, as was
given in humans, up to nine times over the ﬁrst 3 weeks of follow-
up without noting signiﬁcant changes in mouse glycemia (Fig. 2C).
Similarly, lower doses of GAD-alum did not result in a relevant
protection from T1D (Fig. 2C). The broad range of doses tested
(cumulative doses ranging from 1.5 to 180 mg in RIP-GPmice and 2e
40 mg in NOD mice) suggests that the failure of GAD-alum to pre-
vent T1D was not primarily a question of the dose administered.
Mechanistically, we have shown that treatment with GAD-alum
led to concomitant increase in Foxp3þ Treg and decrease in TNF-
producing ‘autoreactive’ CD8 T-cell populations in the pLN
(Figs. 3A and 4A). Of note, these effects were observed locally but
not systemically, although there was a trend toward increased
percentage of Tregs in the spleen (Figs. 3B and 4B; p ¼ 0.07). Taken
together, these data are consistent with the concept that induction
of immunological tolerance can be achieved through antigen-
speciﬁc approaches locally without the systemic immunecompromise associated with immunosuppressive drugs [34,37]. In
the context of T1D, islet-speciﬁc autoreactive memory T-cells that
cause b-cell death are virtually impossible to eliminate since they
are present in tissues in low numbers and present the same
phenotypic features as other, beneﬁcial memory T-cells that help
the host combat previously encountered pathogens. Hence, if it
were possible to provide patients with a islet-speciﬁc ‘surgical
strike’ it would, if not purge, at least dampen the proinﬂammatory
activities of islet-speciﬁc autoreactive CD8 and CD4 T-cells. None-
theless, the only partial (in respect to TNF) inhibition of LCMV-
speciﬁc CD8 T-cells in pLN (Fig. 3C) is likely responsible for the
lack of protection of GAD-alum treated mice. Moreover, our in vitro
ﬁndings suggest that GAD-alum treatment might not favor the in-
duction of Foxp3-expressing regulatory T-cells with a repertoire
speciﬁc for GAD65 C-terminal region (Fig. 7). Together with the T-
cell cytokine proﬁle biased toward the production of IL-5 (but not
IL-4 or IL-10), we can conclude that GAD-alum treatment elicited
immunomodulatory responses deviated to some extent toward Th2
responses however these induced responses were overall insufﬁ-
cient to provide protection from diabetes in RIP-GP mice.
Due to restricted numbers of protected animals, mechanistic
data with adequately powered stratiﬁcation of responders versus
non-responders to GAD-alum could not be assessed in this study.
Correlative analyses of effector and regulatory T-cell responses in
pLN indicated only a moderate linear relationship that failed to
reach statistical signiﬁcance with 10e11 mice (Fig. 4A, p ¼ 0.098).
While these results in our transgenicmousemodel are encouraging
in the perspective of uncovering potential immune biomarkers that
would be clinically relevant for future trials, the inaccessibility of
the pancreas and pLN in human patients remains a major obstacle
[11]. In this regard, studies by Cheramy et al. have shown that the
cohort of patients from the 2008 intervention trial [21], presented
reduced Th1-associated (IgG1) and augmented Th2-associated
(IgG3/4) isotypes of GAD65-speciﬁc autoantibodies [38], which is
consistent with previous data in mice [39].
In the perspective of reﬁning the experimental strategy for trials
to come, another approach would be to combine the positive yet
sub-optimal outcome of GAD-alum treatment with another reagent
that could either boost pre-existing beneﬁts discussed above or
attack the problem from a different angle. Tian et al. have recently
shown that combination of 100 mg GAD-alum and 6 mg/ml g-
aminobutyric acid (GABA) was able to prolong survival of b-cells
transplanted in recent-onset diabetic NODmice [40]. Of note, lower
doses of either GAD-alum (20 mg, maximal dose used both pres-
ently and in human trials) or GABA (2 mg/ml) failed to provide such
a synergistic effect, again underlining the need for ramp-up studies
in preclinical and clinical trials whenever this is feasible. Other
examples for potential ‘partners’ may include blockade of proin-
ﬂammatory cytokines such as IL-6 or IL-1b, as well as combination
with 1,25-dihydroxyvitamin D3 [41,42], or with a ’response modi-
ﬁer’ inducing IL-10 or transforming growth factor (TGF)-b pro-
duction [37].
Our studies highlight the importance of preclinical studies in the
process that leads from translating promising ﬁndings at the bench
into an efﬁcacious drug in patients. Indeed, although multiple
clinical trials have been done in humans, a very limited amount of
data has been published in mice to explore the mechanism and
immune response to GAD-alum. Further understanding of this
vaccine could provide a more solid rationale or targets for sec-
ondary end-points that would correlate with drug efﬁcacy and
protection from diabetes.
The failure of GAD-alum to prevent T1D in both RIP-GP and NOD
mice implies that subcutaneous injections of an alum-formulated
GAD may not be the best choice of antigen delivery and adjuvant.
Indeed, the choice of the adjuvant and the route of antigen delivery
T. Boettler et al. / Journal of Autoimmunity 44 (2013) 40e48 47might have been major issues that culminated in the failure of the
GAD-alum trials in humans. By reproducing those negative data in
two different mouse models of the disease e in which protection
has already been demonstrated by our lab and others using the
same antigen but different forms of antigen delivery [19,20,25,43e
47]ewe believe that we provide good evidence for the importance
of thorough preclinical evaluations of antigen-speciﬁc vaccines
in T1D.
Taken together, this notion underlines the importance of
formulation, doses, route, and frequencies of administration in
reﬁning GAD-based immunization strategies. Indeed, rather than
focusing on different autoantigens, the available data of GAD-based
immunization strategies in mice suggest that other forms of GAD-
deliverymight be able tohave a sustainedeffect on thecourseof T1D.
5. Conclusions
We have attempted to prevent diabetes onset with GAD-alum
treatments in two mouse models, namely the spontaneous NOD
and the virally induced RIP-GP models. In both cases, we tried a
range of at least 3 doses including that used in human clinical trials.
Consistent with the observations in the clinical trials, GAD-alum
failed to prevent diabetes in the mouse models of T1D. As GAD-
based interventions with different forms of antigen delivery have
previously shown efﬁcacy in mouse models, our ﬁndings suggest
that alum-based interventions might not sufﬁciently support GAD’s
potential to curb autoimmunity in T1D.
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